

subjects by providing alternative drug substances that will be effective against said theramutein.

1. The invention provides a method of determining whether a chemical agent is at least as effective a modulator of a theramutein in a cell as a known substance is a modulator of a corresponding prototheramutein. One embodiment of the method involves contacting a control cell that expresses the prototheramutein and is capable of exhibiting a responsive phenotypic characteristic (linked to the functioning of the prototheramutein in the cell) with the known modulator of the prototheramutein, contacting a test cell that expresses the theramutein and is also capable of exhibiting the responsive phenotypic characteristic (linked to the functioning of the theramutein in the cell) with the chemical agent, and comparing the response of the treated test cell with the response of the treated control cell; to determine that the chemical agent is at least as effective a modulator of the theramutein as the known substance is a modulator of the prototheramutein. In certain other embodiments, one type of control cell may not express the prototheramutein at all. In other embodiments, the control cell may express about the same amount of the prototheramutein as the test cell expresses of the theramutein. In still other embodiments, the control cell may be capable of exhibiting the responsive phenotypic characteristic to about the same extent as the test cell under certain conditions.

2. Theramuteins of the invention that are of particular interest are those involved in regulatory function, such as enzymes, protein kinases, tyrosine kinases, receptor tyrosine kinases, serine threonine protein kinases, dual specificity protein kinases, proteases, matrix metalloproteinases, phosphatases, cell cycle control proteins, docking proteins such as the IRS family members, cell-surface receptors, G-proteins, ion channels, DNA- and RNA-binding proteins, polymerases, and the like. No limitation is intended on the type of theramutein that may be used in the invention. At the present time, three theramuteins are known: BCR-ABL, c-Kit, and EGFR.

3. Any responsive phenotypic characteristic that can be linked to the presence of the theramutein (or prototheramutein) in the cell can be employed for use in the method, including, for example, growth or culture properties, the phosphorylation state (or other modification) of a substrate of the theramutein, and any type of transient characteristic of the cell, as will be defined and discussed in detail

DESCRIPTION OF THE FIGURES

[0017] Figure 1 shows the effect on growth and viability of different concentrations of Compound 2 (C2) for non-transformed vector control Ba/F3 cells (which are IL-3 dependent) as well as Ba/F3 cells expressing the "wild type" p210^{Bcr-Abl} (designated p210^{Bcr-Abl-wt}), and Ba/F3 cells expressing the p210^{Bcr-Abl-T315I} drug resistant mutant. Cell counts and viability were determined on an automated cell counter as discussed in detail in the specification. Cell counts are shown by the solid color bars; cell viability is shown by the hashed bars. Note that STI-571 potently inhibits growth of the P210 cell line (grey bar) whereas it is unable to inhibit the growth of the T315I cell line (white bar) even at 10 μ M concentration. 500 nM C2 shows the largest specificity gap within this dose-response series. Compare STI-571 at 10 μ M to C2 at 500 nM on the T315I cell line (white bars).

Abbreviations: DMSO: dimethylsulfoxide (solvent used for drug dissolution).

[0018] Figure 2 shows the effect on growth and viability of different concentrations of Compound 6 (C6) for non-transformed vector control Ba/F3 cells as well as Ba/F3 cells expressing the p210^{Bcr-Abl-T315I} drug resistant mutant. All other details are as per Fig. 1.

[0019] Figure 3 shows various determinations of the specificity gap by comparing the effects of various compounds identified in the screen in terms of their effects on the prototheramutein- and theramutein-expressing cell lines. Compound 3 (C3) shows the best example of the ability of the method to identify a compound that exerts an even greater effect on the theramutein than on its corresponding prototheramutein. (Panel E). Panel A: control DMSO treatments; B: negative heterologous specificity gap; C: slightly positive heterologous specificity gap; D: large positive homologous specificity gap; E: positive heterologous specificity gap. See text for explanations.

[0020] Figure 4 shows an autoradiograph of recombinant P210 Bcr-Abl wild type and T315I mutant kinase domains assayed for autophosphorylation activity. 200 ng of protein were preincubated with test substances for 10 minutes under standard autophosphorylation reaction conditions and then radiolabelled ATP was added and the reactions proceeded for 30 minutes at 30°C, after which the samples were separated by SDS-PAGE. The gels were silver-stained, dried down under vacuum and exposed to X-ray film. Note that whereas 10 μ M STI 571 is effective against wild type P210 Bcr-Abl, it is virtually ineffective against the T315I kinase domain, even at concentrations up to 100 μ M. C2 and C6 are the best two

Y is selected from a chemical bond, O, NR^0 ,

R^6 is selected from alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, and a heterocyclic ring;

Z is a hydrocarbon chain having from 1 to 4 carbon atoms, and optionally substituted with one or more of halo, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, CO_2R^0 , $\text{C}(\text{O})\text{R}^0$, $\text{C}(\text{O})\text{N}(\text{R}^0)_2$, CN, CF_3 , $\text{N}(\text{R}^0)_2$, NO_2 , and OR^0 ;

R^7 is H or is selected from aryl and a heterocyclic ring;

each R^0 is independently selected from H, alkyl, cycloalkyl, aralkyl, aryl and a heterocyclic ring;

a is 1 or 2;

b is 0 or 1;

c is 1 or 2;

d is 0 or 1;


e is 1 or 2; and

f is 0 or 1.

[0041] An important component and conceptual teaching of the Invention described herein is that neither the R^2 nor the R^3 positions of the compounds of this invention are members of any aromatic or non-aromatic ring structure. We have discovered that compounds having the R^2 and/or the R^3 positions as members of any aromatic or non-aromatic ring structure do not effectively inhibit the T315I theramutein, whereas the compounds of the invention that lack such a ring component at these positions, in addition to having other preferred chemical groups, are potent inhibitors of the T315I theramutein.


[0042] In preferred embodiments of the invention, ring A is an aromatic ring.

[0043] In preferred embodiments of the invention, X^1 or X^2 is N. In another preferred embodiment, both X^1 and X^2 are N. In particularly preferred embodiments of the invention Ring A is a pyridine ring or a pyrimidine ring. In still further preferred embodiments, Ring A is selected from the structures provided below:




chemistry would be readily familiar with the procedures and techniques necessary to accomplish the synthetic approaches given below.

[0072] Embodiments wherein $R^2 = \text{NH}$, $R^3 = \text{N}$, $R^4 = \text{CH}$, and $R^5 = \text{-aryl}$ may be prepared by reaction of an appropriate hydrazine compound, such as **A**, and an appropriate aldehyde, such as **B**, under conditions similar to those described on p. 562 of Gineinah, *et al.* (Arch. Pharm. Med. Chem. 2002, 335, 556-562).



For example, heating **A** with 1.1 equivalents of **B** for 1 to 24 hours in a protic solvent such as a C_1 to C_6 alcohol, followed by cooling and collection of the precipitate, would afford **C**. Alternatively, product **C** may be isolated by evaporation of the solvent and purification by chromatography using silica gel, alumina, or C_4 to C_{18} reverse phase medium. Similar methodology would be applicable in the cases where "Aryl" is replaced by other groups defined under R^5 .


[0073] Embodiments wherein $R^2 = \text{NH}$, $R^3 = \text{NR}^{32}$, $R^4 = \text{C(O)}$, and $R^5 = \text{a heterocyclic ring}$ may be prepared by reaction of an appropriate hydrazine compound, such as **D**, and an activated carboxylic acid such as **E**, wherein LG is a leaving group such as halo, 1-oxybenztriazole, pentafluorophenoxy, *p*-nitrophenoxy, or the like, or Compound **E** may also be a symmetrical carboxylic acid anhydride, whereby conditions similar to those described on p. 408 of Nair and Mehta (Indian J. Chem. 1967 5, 403-408) may be used.



For example, treatment of **D** with an active ester such as Heterocycle- $\text{C(O)-OC}_6\text{F}_5$ in an inert solvent such as dichloromethane, 1,2-dichloroethane, or *N,N*-dimethylformamide, optionally in the presence of a base such as pyridine or another tertiary amine, and optionally in the presence of a catalyst such as 4-*N,N*-dimethylaminopyridine, at an appropriate temperature

ranging from 0° C to the boiling point of the solvent, would afford *F*, which may be isolated by evaporation of the solvent followed by chromatography using silica gel, alumina, or C₄ to C₁₈ reverse phase medium. The above active ester example of *E* would be readily prepared from the corresponding carboxylic acid and pentafluorophenol using a carbodiimide such as dicyclohexylcarbodiimide as a condensing agent. Similar methodology would be applicable in the cases where "Heterocycle" is replaced by other groups defined under R⁵.

[0074] Precursors such as *A* and *D* may be prepared by reaction of an appropriate nucleophile, for example, a hydrazine derivative, with a heteroaromatic compound bearing a halo substituent at a position adjacent to a nitrogen atom. For example, using methods analogous to those described by Wu, *et al.* (J. Heterocyclic Chem. 1990, 27, 1559-1563), Breshears, *et al.* (J. Am. Chem. Soc. 1959, 81, 3789-3792), or Gineinah, *et al.* (Arch. Pharm. Med. Chem. 2002, 335, 556-562), examples of compounds *A* and *D* may be prepared starting from, for example, a 2,4-dihalopyrimidine derivative, many of which are commercially available or are otherwise readily prepared by one skilled in the art. Thus, treatment of an appropriate 2,4-dihalopyrimidine derivative *G* with an amine or other nucleophile (Z), optionally in the presence of an added base, selectively displaces the 4-halo substituent on the pyrimidine ring. Subsequent treatment of the product with a second nucleophilic reagent such as hydrazine or a hydrazine derivative, optionally in a solvent such as a C₁ to C₆ alcohol and optionally in the presence of an added base, displaces the 2-halo substituent on the pyrimidine ring, to afford compounds that are examples of structures *A* and *D* above.



[0075] Embodiments wherein R² is -NR²² and R³ is -C(=R³³) can be synthesized by methods such as the following, or straightforward modifications thereof. The synthesis may be conducted starting from an appropriate ring A derivative *J* that bears a leaving group (LG) adjacent to the requisite ring nitrogen. Structure *G* above and the product of reaction of structure *G* with nucleophile Z, as illustrated above, are examples of such appropriate Ring A derivatives *J*. Suitable LG' groups are halo, alkylthio, alkylsulfonyl, alkylsulfonate or

activator may be partial or complete. Likewise, as used herein, the terms "antagonist" and "inhibitor" of a protein are used interchangeably. An inhibitor (antagonist) is limited to a substance that binds to and inhibits the functioning of a given protein. To state that a substance "inhibit(s)" a protein means the substance binds to the protein and reduce(s) the protein's activity in the cell without materially reducing the amount of the protein in the cell. Similarly, to state that a substance "activate(s)" a protein, such as a prototheramutein or theramutein, is to state that the substance increased the defined function of the protein in the cell without substantially altering the level of the protein in the cell. Unless explicitly stated otherwise, an "inhibitor", an "antagonist" and an "inhibitor of a protein" are also synonymous. The inhibition by an inhibitor may be partial or complete. A modulator is an activator or an inhibitor. By way of example, an "activator of PKC β_1 " should be construed to mean a substance that binds to and activates PKC β_1 . Similarly, an "inhibitor of p210^{Bcr-Abl}" is a substance that binds to and inhibits the functioning of p210^{Bcr-Abl}. To state that a substance "inhibits a protein" requires that the substance bind to the protein in order to exert its inhibitory effect. Similarly, to state that a substance "activates protein X" is to state that the substance binds to and activates protein X. The terms "bind(s)," "binding," and "binds to" have their ordinary meanings in the field of biochemistry in terms of describing the interaction between two substances (e.g., enzyme-substrate, protein-DNA, receptor-ligand, etc.). As used herein, the term "binds to" is synonymous with "interacts with" in the context of discussing the relationship between a substance and its corresponding target protein. As used herein, to state that a substance "acts on" a protein, "affects" a protein, "exerts its effect on" a protein, etc., and all such related terms uniformly mean (as the skilled investigator is well aware) that said substance activates or inhibits said protein.

[0094] The concept of inhibition or activation of a mutated form of an endogenous protein to a greater extent than the corresponding non-mutated counterpart protein is defined for the first time and referred to herein as a positive "*specificity gap*." In general terms, *and using an inhibitor case as an example*, the *specificity gap* refers to the difference between the ability of a given substance, under comparable conditions to inhibit the theramutein in a cell-based assay system as compared to either:

a) the ability of the same substance under comparable conditions to inhibit the prototheramutein, or

- b) the ability of a second substance (usually a known inhibitor of the prototheramutein) to inhibit the theramutein under comparable conditions, or
- c) the ability of the second substance to inhibit the prototheramutein under comparable conditions.

[0095] When the comparison is made between the effects of two distinct substances (tested individually) on the theramutein alone, the result is termed a *homologous specificity gap* determination.

[0096] Alternatively, when a comparison is made between the effects of two distinct substances (generally, but not always), one of which is tested on the theramutein and the other on the prototheramutein, respectively, the result is termed a *heterologous specificity gap* (SG) determination. Thus, (a) and (c) as given above are examples of heterologous specificity gap (SG) determinations (although (a) uses the same substance in both instances), whereas (b) is an example of a homologous specificity gap determination.

[0100] Reference to Figure 3 is informative in understanding and elucidating these concepts.

[0101] Analogous issues apply when the case concerns an activator. It will be immediately obvious to the skilled artisan that the term "comparable conditions" includes testing two different compounds, for example, at the same concentration (such as comparing two closely related compounds to determine relative potency), or by comparing the effects of two different compounds tested at their respective IC₅₀ values on the corresponding prototheramutein and theramutein. The skilled investigator will easily recognize other useful variations and comparable conditions.

[0102] Thus, in one embodiment of the application of this approach, substances that are more effective against a theramutein have a "positive specificity gap." A "zero, null or no" specificity gap indicates that there is no significant measurable difference between the effect of a substance on the theramutein as compared to its effect on the prototheramutein (however such compounds may be quite useful in their ability to inhibit or activate both a theramutein and its corresponding prototheramutein), and a "negative specificity gap" indicates a substance that at a given concentration is less effective against the given theramutein than against a form of the corresponding prototheramutein or other comparative form of the theramutein (such as one that may harbor a different mutation). The latter category is generally of lesser interest than the former categories of compounds, except in the

to STI-571. Hence purely and simply, the Huron methodology failed to identify an effective inhibitor of the p210^{Bcr-AblT315I} theramutein.

[0109] Indeed, prior to the disclosure of this invention, including both the detailed methodology described for the first time herein as well as the compositions provided herein, *no one anywhere in the world* has been successful in identifying a chemical agent, let alone a methodology that is capable of identifying a chemical agent that effectively inhibits the p210^{Bcr-AblT315I} theramutein to an equal or greater extent than STI-571 is able to do with respect to the wild type p210^{Bcr-Abl} protein. (See Shah et al., Science, July, 2004; O'Hare et al., Blood, 2004; Tipping et al., Leukemia, 2004; Weisberg et al., Leukemia, 2004).

[0110] It cannot be overemphasized that such compounds would be immensely useful, because at the present time there is no alternative for patients who progress to p210^{Bcr-Abl-T315I} theramutein-mediated imatinib mesylate-resistant status. *Once patients develop such resistance, there is no other effective alternative treatment available, and death is certain. The method described herein provides the first reported approach to identify, pharmacologically characterize and chemically synthesize effective inhibitors of the p210^{Bcr-Abl-T315I} theramutein. Moreover, the skilled investigator will immediately recognize the applicability and generalizability of this approach to any highly drug-resistant theramutein.*

[0111] In the present invention, a test cell is used that displays a carefully selected phenotypic characteristic (as defined below) which is linked to the presence and functional activity of the particular theramutein-of-interest (TOI) in the cell under appropriate conditions. This should be qualitatively the same as the phenotypic characteristic displayed by a cell that expresses the prototheramutein. A phenotypic characteristic (i.e. a non-genotypic characteristic of the cell) is a property which is observed (measured), selected and/or defined for subsequent use in an assay method as described herein. Expression of the phenotypic characteristic is responsive to the total activity of the theramutein in the cell, and is a result of the absolute amount of the theramutein and its specific activity. Often, the phenotypic characteristic is observable as a result of elevated levels of theramutein activity and is not apparent in cells that express low amounts of the theramutein or low amounts of its corresponding prototheramutein. Further, it can often be demonstrated that the phenotypic characteristic is modulated by modulating the specific activity of the theramutein with an inhibitor or activator of the theramutein, although this is not always the case since an inhibitor or activator of the TOI may not always be available at the time the skilled

selected protein. Such a responsive phenotypic characteristic is referred to herein as a “phenoresponse.”

[0117] Though not always necessary, it will often be advantageous to employ cells that express high levels of the theramutein, and to select a phenotypic characteristic that results from overexpression of the theramutein. This is because phenotypic characteristics linked to the functioning of the theramutein generally become more distinguishable (easier to measure) as a theramutein is overexpressed to a greater extent. Further, phenoresponses that are observed in response to modulators of the theramutein are often amplified as the functional level of the theramutein is increased. Expressed another way, the selected phenoresponse observed in cells that overexpress the theramutein is particularly sensitive to modulators of the theramutein.

[0118] Preferably, the theramutein is stably expressed in a test cell. Stable expression results in a level of the theramutein in the cell that remains relatively unchanged during the course of an assay. For example, stimulation or activation of a component of a signaling pathway may be followed by a refractory period during which signaling is inhibited due to down-regulation of the component. For theramuteins of the invention, such down-regulation is usually sufficiently overcome by artificially overexpressing the theramutein. Expressed another way, the expression is sufficiently maintained that changes in a phenotypic characteristic that are observed during the course of an assay are due primarily to inhibition or activation of the theramutein, rather than a change in its level, even if down-modulation of the theramutein subsequently occurs. For these reasons, although stable expression of the theramutein is preferred, transfection followed by transient expression of the theramutein may be employed provided that the selected phenotypic characteristic is measurable and the duration of the assay system is short relative to the progressive decline in the levels of the transiently expressed theramutein which is to be expected in such systems over time. For these reasons, stably expressing cell lines are preferred (U.S. Patent No. 4,980,281).

[0119] A preferred drug screening method of the present invention involves the following:

[0120] 1) Identification of a theramutein for which a novel inhibitor or activator is desired. Identification of an appropriate theramutein may be performed using standard techniques (See, Gorre et al., Science, 2001; see also PCT/US02/18729). Briefly, patients that have been given a course of a therapeutically effective treatment using an activator or

methodology. (Gorre et al., 2001; Housey et al., 1988). In one embodiment, overexpression results in a level of the theramutein that is at least about 3 times the amount of the protein usually present in a cell. Alternatively, the amount is at least about 10 times the amount usually present in a cell. In another embodiment, the amount is at least about 20 times or more preferably at least about 50 times the amount usually present in a cell.

[0122] 3) Provision of a control cell that expresses the prototheramutein corresponding to the theramutein of interest. As some of the muteins that are described herein are also enzymes, they usually retain catalytic activity, and therefore the control cell usually displays substantially the same phenotypic characteristic as the test cell. The phenotypic characteristic need not be quantitatively alike in both cells, however. For example, a mutation that leads to reactivation of the prototheramutein may also increase, decrease, or otherwise affect its specific activity with respect to one or more of its substrates in the cell. As a result, it may exhibit the selected phenotypic characteristic to a greater or lesser extent. Accordingly, it may be desirable in some cases to adjust expression of either or both of the prototheramutein and the theramutein such that test and control cells exhibit the phenotypic characteristic to approximately the same degree. This may be done, for example, by expressing the proteins from promoters whose activity can be adjusted by adjusting the amount of inducer present, all using standard methodology (see, for example, Sambrook et al. 1989 & 2001).

[0123] It will be obvious to one of ordinary skill in the art that a properly defined phenoresponse may be *quantitatively* different between the prototheramutein- and the theramutein-expressing cell lines as a result of differences in the specific activity (if any) between the theramutein and its corresponding prototheramutein. Theramutein-inducing mutations may increase or decrease the specific activity of said theramutein relative to the corresponding prototheramutein. When comparing a theramutein expressing cell line with a prototheramutein expressing cell line, it is preferable that the selected phenoresponse is qualitatively the same in both cell types. Thus, the skilled investigator may choose to normalize the activity of the theramutein-expressing cell line to that of the prototheramutein-expressing cell line, or vice versa. Such normalization methods are standard in the art. See, for example, Bolstad et al. (2003).

[0124] Alternatively, the skilled investigator may also wish to use unmodified host cells or host cells harboring the expression vector only as control cells for certain

experimental procedures. (The host cells are the cells into which an expression vector encoding the theramutein was introduced in order to generate the test cells.) This may be the case where the investigator is only interested in identifying a specific inhibitor or activator of the theramutein of interest, irrespective of whether or not said compound is also active effective the prototheramutein of interest (pTOI).

[0125] 4) The test and control cells are then maintained or propagated (although not necessarily at the same time) in growth media (or even in intact animals) under suitable conditions such that the phenoresponse may be expressed and assayed. Control cells that are expressing the prototheramutein may be treated with a known modulator of the prototheramutein, or with a test substance, and test cells are treated with test compounds to determine whether they are active against the theramutein, as measured by the ability of said substances to modulate the phenoresponse in the expected manner. Alternatively, control cells not expressing the prototheramutein may also be substituted, depending upon the particular phenoresponse that the skilled investigator has chosen for study. Substances may then be assayed on the test cells and, optionally, on the control cells at the same time, or at another time, and the results compared.

[0126] In one embodiment of the invention, substances that are active with regard to the test cells can be rapidly identified by their ability to modulate the phenoresponse of the test cells in the same manner as, for example, the known modulator of the prototheramutein alters the phenoresponse of prototheramutein-expressing control cells. In another embodiment, active substances may be identified by their ability to modulate the activity of the theramutein in the test cells while having little or no effect on the unmodified (prototheramutein and/or theramutein non-expressing) control cells. The skilled investigator will readily appreciate the many variations of this approach that may be utilized to identify, for example, modulators that are more effective against the theramutein, or that are equally effective against both the prototheramutein and one or more corresponding specific theramuteins.

[0127] Other phenoresponses can be observed and/or measured and include, for example, detection of substrates of the prototheramutein, and detection of gene expression changes that are regulated by the activity of the theramutein. In the simplest terms, any characteristic of the cell that the skilled investigator has previously correlated with the functional activity of the theramutein may be suitable for use with such methods. However,

agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, anti survival agents, biological response modifiers, anti-hormones, and anti-angiogenesis agents, all of which can be administered with inhibitors or activators of theramuteins.

[0137] A modulator of a theramutein can be administered with antibodies that neutralize other receptors involved in tumor growth. Further, a modulator of a theramutein can be administered with a compound that otherwise modulates a component of a signal transduction pathway, preferably a component of the signal transduction pathway in which the theramutein is active and which is common to one or more other signal transduction pathways. In an embodiment of the invention, a theramutein modulator is used in combination with a receptor antagonist that binds specifically to the Epidermal Growth Factor Receptor (EGFR). Particularly preferred are antigen-binding proteins that bind to the extracellular domain of EGFR and block binding of one or more of its ligands and/or neutralize ligand-induced activation of EGFR. An EGFR antagonist can be an antibody that binds to EGFR or a ligand of EGFR and inhibits binding of EGFR to its ligand. Ligands for EGFR include, for example, EGF, TGF- α , amphiregulin, heparin-binding EGF (HB-EGF) and betacellulin. EGF and TGF- α are thought to be the main endogenous ligands that result in EGFR-mediated stimulation, although TGF- α has been shown to be more potent in promoting angiogenesis. It should be appreciated that the EGFR antagonist can bind externally to the extracellular portion of EGFR, which can or can not inhibit binding of the ligand, or internally to the tyrosine kinase domain in the case of chemical agents. Examples of EGFR antagonists that bind EGFR include, without limitation, biological agents such as antibodies (and functional equivalents thereof) specific for EGFR, and chemical agents (small molecules), such as synthetic kinase inhibitors that act directly on the cytoplasmic domain of EGFR.

[0138] Other examples of growth factor receptors involved in tumorigenesis are the receptors for vascular endothelial growth factor (VEGFR-1 and VEGFR-2), platelet-derived growth factor (PDGFR), nerve growth factor (NGFR), fibroblast growth factor (FGFR), and others.

[0139] In a combination therapy, the theramutein inhibitor is administered before, during, or after commencing therapy with another agent, as well as any combination thereof, *i.e.*, before and during, before and after, during and after, or before, during and after

commencing the anti-neoplastic agent therapy. For example, the theramutein inhibitor can be administered between 1 and 30 days, preferably 3 and 20 days, more preferably between 5 and 12 days before commencing radiation therapy. In a preferred embodiment of the invention, chemotherapy is administered prior to, concurrently with or, more preferably, subsequent to antibody therapy.

[0140] In the present invention, any suitable method or route can be used to administer theramutein inhibitors of the invention, and optionally, to co-administer anti-neoplastic agents and/or antagonists of other receptors. The anti-neoplastic agent regimens utilized according to the invention, include any regimen believed to be optimally suitable for the treatment of the patient's neoplastic condition. Different malignancies can require use of specific anti-tumor antibodies and specific anti-neoplastic agents, which will be determined on a patient to patient basis. Routes of administration include, for example, oral, intravenous, intraperitoneal, subcutaneous, or intramuscular administration. The dose of antagonist administered depends on numerous factors, including, for example, the type of antagonists, the type and severity of the tumor being treated and the route of administration of the antagonists. It should be emphasized, however, that the present invention is not limited to any particular method or route of administration.

[0141] Suitable carriers include, for example, one or more of water, saline, phosphate buffered saline, dextrose, glycerol, ethanol and the like, as well as combinations thereof. Carriers can further comprise minor amounts of auxiliary substances, such as wetting or emulsifying agents, preservatives or buffers, which enhance the shelf life or effectiveness of the theramutein modulator as the active ingredient. The compositions can, as is well known in the art, be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the mammal.

[0142] The compositions of this invention can be in a variety of forms. These include, for example, solid, semi-solid and liquid dosage forms, such as tablets, pills, powders, liquid solutions, dispersions or suspensions, liposomes, suppositories, injectable and infusible solutions. The preferred form depends on the intended mode of administration and therapeutic application.

[0143] Such compositions of the present invention are prepared in a manner well known in the pharmaceutical art. In making the composition the active ingredient will usually be mixed with a carrier, or diluted by a carrier and/or enclosed within a carrier which

compound was unavailable for further testing due to lack of availability of additional material from the chemical supplier. The remaining five compounds were independently evaluated in additional cell-based assays using the aforementioned cell lines as well as in a cell-free purified protein kinase assay using human recombinantly produced 120 Kd kinase domain fragments isolated from both wild type P210 Bcr-Abl as well as P210 T315I mutant kinase domain.

[0152] All five compounds inhibited p210^{Bcr-Abl-T315I} 120 Kd activity as measured by inhibition of autophosphorylation activity, as shown in Figure 4. Thus, of the 6 highest scoring compounds out of more than 113,000 compounds screened, at least 5 of the six directly inhibited the p210^{Bcr-Abl-T315I} mutant. It is noteworthy that Compound 5 appears to spread the recombinant protein band out on the SDS page gel. This was also evident on the silver-stained gel (data not shown). It is possible that this compound may actually be a "suicide" inhibitor that is able to covalently cross-link the POI in order to permanently inhibit its activity, but this will require further study.

[0153] Taken together, the teachings and the results described herein provide conclusive proof that the system is capable of identifying inhibitors or activators of the selected theramutein, and the skilled investigator will immediately recognize that such a system may be easily applied to any other theramutein with only obvious, minor modifications.

[0154] Representative examples of the cell-based assay results demonstrating selective inhibition of growth of the Ba/F3 T315I cell line relative to the wild type non-transformed Ba/F3 cells are shown in Figures 1 and 2. The compounds inhibited growth and reduced the viability of cells expressing the T315I theramutein at concentrations under which the growth and viability of the wild type Ba/F3 non-transformed cells (not expressing either p210^{Bcr-Abl-wt} or p210^{Bcr-Abl-T315I}) were relatively unaffected, whereas cells expressing both the prototheramutein as well as the theramutein were substantially inhibited. In some instances, the T315I expressing cells were inhibited to an even greater extent than the P210 prototheramutein expressing cells. (See, for example, Figure 3, right hand side, Compound 3 results against P210 and T315I cells.

[0155] In summary, the methods presented herein provide a fundamental advance in the form of a generalizable approach for creating or identifying modulators of any given theramutein. The results demonstrate conclusively the power of the method to identify

References

Adcock, I.M., Lane, S.J. **Mechanisms of Steroid Action and Resistance in Inflammation.** Journal of Endocrinology, Volume 178 (September 2003) Pages 347-355

Allen, P.B., Wiedemann, L.M. **An Activating Mutation in the ATP Binding Site of the ABL Kinase Domain.** The Journal of Biological Chemistry, Volume 271 (August 9, 1996) Pages 19585-19591

Barthe, C., Cony-Makhoul, P., Melo, J.V., Reiffers, J., Mahon, F.X. **Roots of Clinical Resistance to STI- 571 Cancer Therapy.** Science, Volume 293 (September 21, 2001) Page 2163a

Berge, S.M., Bighley, L.D., Monkhouse, D.C. **Pharmaceutical salts.** Journal of Pharmaceutical Science, Volume 66 (January 1977) Pages 1-19.

Bolstad, B.M., Irizarry, R.A., Astrand, M., Speed, T.P. **A Comparison of Normalization Methods for High Density Oligonucleotide Array Data Based on Variance and Bias.** Bioinformatics, Volume 19 (January 22, 2003) Pages 185-193.

Bonifacino, J.S. **Current Protocols in Cell Biology,** Wiley & Sons, New York, 1999

Branford, S., Rudzki, Z., Walsh, S., Grigg, A., Arthur, C., Taylor, K., Hermann, R., Lynch, K.P., Hughes, T.P. **High Frequency of Point Mutations Clustered Within the Adenosine Triphosphate-Binding Region of BCR/ABL in Patients with Chronic Myeloid Leukemia or Ph-positive Acute Lymphoblastic Leukemia Who Develop Imatinib (STI571) Resistance.** Blood, Volume 99 (May 1, 2002) Pages 3472-3475

Breshears, S.R., Wang, S.S., Bechtolt, S.G., Christensen, B.E. **Purines. VIII: The Aminolysis of Certain Chlorosubstituted Purines.** Journal of the American Chemical Society, Volume 81 (July 20, 1959) Pages 3789-3792

Capps, T.M., Heard, N.E., Simmons, D.P., Connor, C.L. **Identification and Synthesis of a Unique Disulfide Dimeric Metabolite of Primisulfuron-methyl in the Mouse.** Journal of Agricultural and Food Chemistry, Volume 41 (1993) Pages 2411-2415

Coligan, J. **Current Protocols in Immunology,** Wiley & Sons, New York, 1994

Corbin, A.S., Buchdunger, E., Pascal, F., Druker, B.J. **Analysis of the Structural Basis of Specificity of Inhibition of the Abl Kinase by STI571.** The Journal of Biological Chemistry, Volume 277 (August 30, 2002) Pages 32214-32219

Cunningham, B.C., De Vos, A.M., Mulkerrin, M.G., Ultsch, M., Wells, J.A. **Selecting Ligand Agonists and Antagonists.** U.S. Patent 5,506,107 (April 9, 1996)

Cunningham, B.C., Wells, J.A., Clark, R. G., Olson, K., Fuh, G.G. **Method for Inhibiting Growth Hormone Action.** U.S. Patent 6,004,931 (December 21, 1999)

Daley, G.Q., Van Etten, R.A., Baltimore, D. **Induction of Chronic Myelogenous Leukemia in Mice by the P210^{bcr/abl} Gene of the Philadelphia Chromosome.** Science, Volume 247 (February 16, 1990) Pages 824-830

Davis, T.L. **The Mechanism of Reactions in the Urea Series.** Proceedings of the National Academy of Sciences of the United States of America, Volume 11 (1925) Pages 68-73

Druker, B.J., M.D., Sawyers, C.L., M.D., Kantarjian, H., M.D., Resta, D. J., R.N., Reese, S.F., M.D., Ford, J.M., M.D., Capdeville, R., M.D., Talpaz, M., M.D. **Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome.** The New England Journal of Medicine, Volume 344 (April 5, 2001) Pages 1038-1042

Druker, B.J., M.D., Talpaz, M., M.D., Resta, D.J., R.N., Peng, B., Ph.D., Buchdunger, E., Ph.D., Ford, J.M., M.D., Lydon, N.B., Ph.D., Kantarjian, H., M.D., Capdeville, R., M.D., Ohno-Jones, S., B.S., Sawyers, C. L., M.D. **Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia.** The New England Journal of Medicine, Volume 344 (April 5, 2001) Pages 1031-1037

Druker, B.J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G.M., Fanning, S., Zimmermann, J., Lydon, N.B. **Effects of a Selective Inhibitor of the Abl Tyrosine Kinase on the Growth of Bcr-Abl Positive Cells.** Nature Medicine, Volume 2 (May 1996) Pages 561-566

Enna, S.J. **Current Protocols in Pharmacology**, Wiley & Sons, New York, 1991

Faderl, S., M.D., Talpaz, M., M.D., Estrov, Z., M.D., O'Brien, S., M.D., Kurzrock, R., M.D., Kantarjian, H. M., M.D. **The Biology of Chronic Myeloid Leukemia.** The New England Journal of Medicine, Volume 341 (July 15, 1999) Pages 164-172

Foreman, J.C. and Johansen, T. **Textbook of Receptor Pharmacology.** CRC Press, Boca Raton, 2002

Gambacorti-Passerini, C., Barni, R., Le Coutre, P., Zucchetti, M., Cabrita, G., Cleris, L., Rossi, F., Gianazza, E., Brueggen, J., Cozens, R., Pioltelli, P., Pogliani, E., Corneo, G., Formelli, F., D'Incalci, M. **Role of $\alpha 1$ Acid Glycoprotein in the *In Vivo* Resistance of Human BCR-ABL⁺ Leukemic Cells to the Abl Inhibitor STI571.** Journal of the National Cancer Institute, Volume 92 (October 18, 2000) Pages 1641-1650

Gineinah, M.M., El-Sherbeny, M.A., Nasr, M.N., Maarouf, A.R. **Synthesis and Antiinflammatory Screening of Some Quinazoline and Quinazolyl-4-oxoquinazoline Derivatives.** Archiv der Pharmazie – Pharmaceutical and Medicinal Chemistry, Volume 335 (2002) Pages 556-562

Gorre, M.E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P.N., Sawyers, C.L. **Clinical Resistance to STI- 571 Cancer Therapy Caused by BCR- ABL Gene Mutation or Amplification.** Science, Volume 293 (August 3, 2001) Pages 876-880

Greene, T.W.; Wuts, P.G.M. **Protective Groups in Organic Synthesis**, 2nd ed., Wiley, New York, 1991

Hofmann, W.K., Jones, L.C., Lemp, N.A., DeVos, S., Gschaidmeier, H., Hoelzer, D., Ottmann, O. G., Koefler, H. P. **Ph⁺ Acute Lymphoblastic Leukemia Resistant to the Tyrosine Kinase Inhibitor STI571 has a Unique BCR-ABL Gene Mutation.** Blood, Volume 99 (March 1, 2002) Pages 1860-1862

Horowitz, A.D., Greenebaum, E., Weinstein, I.B. **Identification of Receptors for Phorbol Ester Tumor Promoters in Intact Mammalian Cells and of an Inhibitor of Receptor Binding in Biologic Fluids.** Proceedings of the National Academy of Sciences of the United States of America, Volume 78 (April 1981) Pages 2315-2319

Hou, Y.Y., Tan, Y.S., Sun, M.H., Wei, Y.K., Xu, J.F., Lu, S.H., A-Ke-Su, S.J., Zhou, Y.N., Gao, F., Zheng, A.H., Zhang, T.M., Hou, W.Z., Wang, J., Du, X., Zhu, X.Z. **C-kit Gene Mutation in Human Gastrointestinal Stromal Tumors.** World Journal of Gastroenterology, Volume 10 (May 1, 2004) Pages 1310-1314

Housey, G.M. **Method of Screening for Protein Inhibitors and Activators.** U.S. Patent 4,980,281 (December 25, 1990)

Housey, G.M. **The Role of Protein Kinase C in Growth Control and Tumor Promotion.** Ph.D. Dissertation, (1988)

Housey, G.M., Johnson, M.D., Hsiao, W.L., O'Brian, C.A., Murphy, J.P., Kirschmeier, P., Weinstein, I. B. **Overproduction of Protein Kinase C Causes Disordered Growth Control in Rat Fibroblasts.** Cell, Volume 52 (February 12, 1988) Pages 343-354

Huron, D.R., Gorre, M.E., Kraker, A.J., Sawyers, C.L., Rosen, N., Moasser, M.M. **A Novel Pyridopyrimidine Inhibitor of Abl Kinase is a Picomolar Inhibitor of Bcr-Abl-driven K562 Cells and is Effective Against STI571-resistant Bcr-Abl Mutants.** Clinical Cancer Research, Volume 9 (April 2003) Pages 1267-1273

La Rosee, P., Corbin, A.S., Stoffregen, E.P., Deininger, M.W., Druker, B.J. **Activity of the Bcr-Abl Kinase Inhibitor PD180970 Against Clinically Relevant Bcr-Abl Isoforms That Cause Resistance to Imatinib Mesylate (Gleevec, STI-571).** Cancer Research, Volume 62 (December 15, 2002) Pages 7149-7153

Latham, H.G. Jr., May, E.L., Mosettig, E. **Amino – and Guanidino-Phenylglucosides.** Journal of Organic Chemistry, Volume 15 (1950) Pages 884-889

Le Coutre, P., Tassi, E., Varella-Garcia, M., Barni, R., Mologni, L., Cabrita, G., Marchesi, E., Supino, R., Gambacorti-Passerini, C. **Induction of Resistance to the Abelson Inhibitor STI571 in Human Leukemic Cells Through Gene Amplification.** Blood, Volume 95 (March 1, 2000) Pages 1758-1766

Leonard, G.D., Fojo, T., Bates, S.E. **The Role of ABC Transporters in Clinical Practice.** The Oncologist, Volume 8 (2003) Pages 411-424

Loutfy, M.R., Walmsley, S.L. **Salvage Antiretroviral Therapy in HIV Infection.** Expert Opinion, Volume 3 (February 2002) Pages 81-90

- Lynch, T.J., M.D., Bell, D.W., Ph.D., Sordella, R., Ph.D., Gurubhagavatula, S., M.D., Okimoto, R.A., B.S., Brannigan, B.W., B.A., Harris, P.L., M.S., Haserlat, S.M., B.A., Supko, J.G., Ph.D., Haluska, F.G., M.D., Ph.D., Louis, D.N., M.D., Christiani, D.C., M.D., Settleman, J., Ph.D., Haber, D.A., M.D., Ph.D. **Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib.** The New England Journal of Medicine, Volume 350 (May 20, 2004) Pages 2129-2139
- Mahon, F.X., Deininger, M.W.N., Schultheis, B., Chabrol, J., Reiffers, J., Goldman, J.M., Melo, J.V. **Selection and Characterization of BCR-ABL Positive Cell Lines with Differential Sensitivity to the Tyrosine Kinase Inhibitor STI571: Diverse Mechanisms of Resistance.** Blood, Volume 96 (August 1, 2000) Pages 1070-1079
- Mansky, L.M., Temin, H.M. **Lower In Vivo Mutation Rate of Human Immunodeficiency Virus Type 1 than that Predicted from the Fidelity of Purified Reverse Transcriptase.** Journal of Virology, Volume 69 (August 1995) Pages 5087-5094
- Marshall, J.R., Walker, J. **Experimental Study of Some Potentially Tautomeric 2- and 4(6)-Substituted Pyrimidines.** Journal of the Chemical Society, (1951) Pages 1004-1017.
- Marx, J. **Why a New Cancer Drug Works Well in Some Patients.** Science, Volume 304 (April 30, 2004) Pages 658-659
- Melo, J.V., Myint, H., Galton, D.A., Goldman, J.M. **P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia?** Leukemia, Volume 8 (January 1994) Pages 208-211
- Nair, M.D., Mehta, S.R. **Syntheses and Reactions of Condensed Isoquinolines* - Imidazo, Pyrimido, Triazolo and Tetrazolo Isoquinolines.** Indian Journal of Chemistry, Volume 5 (September 1967) Pages 403-408
- Noble, M.E.M., Endicott, J.A., Johnson, L.N. **Protein Kinase Inhibitors: Insights into Drug Design from Structure.** Science, Volume 303 (March 19, 2004) Pages 1800-1805
- O'Hare, T., Pollock, R., Stoffregen, E.P., Keats, J.A., Abdullah, O.M., Moseson, E.M., Rivera, V.M., Tang, H., Metcalf, C.A. 3rd, Bohacek, R.S., Wang, Y., Sundaramoorthi, R., Shakespeare, W.C., Dalgarno, D., Clackson, T., Sawyer, T.K., Deininger, M.W., Druker, B.J. **Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.** Blood, Volume 104 (October 15, 2004) Pages 2532-2539
- Paez, J.G., Jänne, P.A., Lee, J.C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F.J., Lindeman, N., Boggon, T.J., Naoki, K., Sasaki, H., Fujii, Y., Eck, M.J., Sellers, W.R., Johnson, B.E., Meyerson, M. **EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy.** Scienceexpress (April 29, 2004) Pages 1-4
- Ravandi, F., Cortes, J., Albitar, M., Arlinghaus, R., Qiang, Guo J., Talpaz, M., Kantarjian, H.M. **Chronic myelogenous leukaemia with p185(BCR/ABL) expression: characteristics and clinical significance.** British Journal of Haematology, Volume 107 (December 1999) Pages 581-586

Sambrook, J., Fritsch, E.F., Maniatis, T. **Molecular Cloning: A Laboratory Manual, 2nd ed.**, Cold Spring Harbor Laboratory Press; New York, 1989

Sambrook and Russell, **Molecular Cloning: A Laboratory Manual**. Cold Spring Harbor Laboratory Press, New York, 2001, Volumes 1-3

Sawyers, C.L., Gorre, M.E., Shah, N.P., Nicoll, J. **Mutations in the Bcr-Abl Tyrosine Kinase Associated with Resistance to STI-571**. WO2002US0018729 (US2002000171889)

Sawyers, C.L. M.D. **Chronic Myeloid Leukemia**. The New England Journal of Medicine, Volume 340 (April 29, 1999) Pages 1330-1340

Schindler, T., Bornmann, W., Pellicena, P., Miller, W.T., Clarkson, B., Kuriyan, J. **Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase**. Science, Volume 289 (September 15, 2000) Pages 1938-1942

Senechal, K., Halpern, J., Sawyers, C.L. **The CRKL Adaptor Protein Transforms Fibroblasts and Functions in Transformation by the BCR-ABL Onocogene**. The Journal of Biological Chemistry, Volume 271 (September 20, 1996) Pages 23255-23261

Senechal, K., Heaney, C., Druker, B., Sawyers, C.L. **Structural Requirements for Function of the Crkl Adapter Protein in Fibroblasts and Hematopoietic Cells**. Molecular and Cellular Biology, Volume 18 (September 1998) Pages 5082-5090

Shah, N.P., Tran, C., Lee, F.Y., Chen, P., Norris, D., Sawyers, C.L. **Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor**. Science, Volume 305 (July 16, 2004) Pages 399-401

Shearer, B.G., Lee, S., Franzmann, K.W., White, H.A.R., Sanders, D.C.J., Kiff, R.J., Garvey, E.P., Furfine, E.S. **Conformationally Restricted Arginine Analogues as Inhibitors of Human Nitric Oxide Synthase**. Bioorganic and Medicinal Chemistry Letters, Volume 7 (July 8, 1997) Pages 1763-1768

Tipping, A.J., Baluch, S., Barnes, D.J., Veach, D.R., Clarkson, B.M., Bornmann, W.G., Mahon, F.X., Goldman, J.M., Melo, J.V. **Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate**. Leukemia, Volume 18 (August 2004) Pages 1352-1356

Von Bubnoff, N., Schneller, F., Peschel, C., Duyster, J. **BCR-ABL Gene Mutations in Relation to Clinical Resistance of Philadelphia-Chromosome-Positive Leukemia to STI571: A Prospective Study**. The Lancet, Volume 359 (February 9, 2002) Pages 487-491

Von Bubnoff, N., Veach, D.R., Van Der Kuip, H., Aulitzky, W.E., Sanger, J., Seipel, P., Bornmann, W.G., Peschel, C., Clarkson, B., Duyster, J. **A cell-based screen for resistance of Bcr-Abl positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor**. Blood, Volume 105 (February 15, 2005) Pages 1652-1659

Wakai, T., Kanda, T., Hirota, S., Ohashi, A., Shirai, Y. Hatakeyama, K. **Late Resistance to Imatinib Therapy in a Metastatic Gastrointestinal Stromal Tumour is Associated With a Second KIT Mutation.** British Journal of Cancer, Volume 90 (June 1, 2004) Pages 2059-2061

Weigel, U., Meyer, M., Sebald, W. **Mutant Proteins of Human Interleukin 2: Renaturation Yield, Proliferative Activity and Receptor Binding.** European Journal of Biochemistry, Volume 180 (March 15, 1989) Pages 295-300.

Weisberg, E., Catley, L., Kujawa, J., Atadja, P., Remiszewski, S., Fuerst, P., Cavazza, C., Anderson, K., Griffin, J.D. **Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo.** Leukemia, Volume 18 (December 2004) Pages 1951-1963

Weisberg, E., Griffin, J.D. **Mechanism of Resistance to the ABL Tyrosine Kinase Inhibitor STI 571 in BCR/ABL-Transformed Hematopoietic Cell Lines.** Blood, Volume 95 (June 1, 2000) Pages 3498-3505

Weisberg, E., Manley, P.W., Breitenstein, W., Brugger, J., Cowan-Jacob, S.W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., Kung, A.L., Mestan, J., Daley, G.Q., Callahan, L., Catley, L., Cavazza, C., Azam, M., Neuberg, D., Wright, R.D., Gilliland, D.G., Griffin, J.D. **Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.** Cancer Cell, Volume 7 (February 2005) Pages 129-141

White, M.F., Livingston, J.M., Backer, Lauris, V., Dull, T.J., Ullrich, A., Kahn, C.R. **Mutation of the Insulin Receptor at Tyrosine 960 Inhibits Signal Transmission but Does Not Affect Its Tyrosine Kinase Activity.** Cell, Volume 54 (August 26, 1988) Pages 641-649

Wu, M.T., MacCoss, M., Ikeler, T.J., Hirshfield, J., Arison, B.H., Tolman, R.L. **Annelated Piperazinyl-7,8-dihydro-6H-thiopyrano[3,2-d]pyrimidines.** Journal of Heterocyclic Chemistry, Volume 27 (1990) Pages 1559-1563